Plagiarism costs author five papers in five different journals

An engineering researcher has written about models tackling a range of complex issues — security problems in Iraq, poverty in Europe, and emergency responses to humanitarian crises. But there may be some limits to his expertise: Between 2016 and 2017, five journals have retracted five of his papers, citing plagiarism.

Some of the notices describe the plagiarism as “extensive,” “significant,” and “substantial.” One journal editor, who retracted one of Kubilay Kaptan’s papers last year, told us the paper “was simply a direct copy from an existing one.”

The editor noted that Kaptan — who lists his affiliation as the Civil Engineering Department at Beykent University in Istanbul — claimed to be “the victim of a personal smear campaign, which involved submitting plagiarised manuscripts in his name.” We reached out to Kaptan several times by phone and email to verify this claim, but did not hear back.

Here’s the most recent retraction, for a 2016 paper published in Journal of Refugee Studies  Continue reading Plagiarism costs author five papers in five different journals

Journal retracts two papers by authors who lifted others’ data

A journal has retracted two 2014 papers after the editors discovered the authors used data from other research groups without permission.

The papers, both published in the same issue of Cell Biochemistry and Biophysics and retracted in May, suffered from similar issues—the authors published data that was not theirs. The authors are all based at different institutions in China; as far as we can tell, the papers do not have any authors in common.

When we asked the publisher whether a third party, such as a paper mill, may have been involved, a spokesperson for Springer told us: Continue reading Journal retracts two papers by authors who lifted others’ data

Springer purge of fake reviews takes down 10+ more neuroscience papers

Back in April, Springer retracted a record number 107 papers from Tumor Biology after uncovering evidence they were subject to fake peer reviews. But it appears that the Tumor Biology sweep was only part of the story.

During the Tumor Biology investigation, Springer found evidence that the “peer review process was compromised” in a dozen papers on brain cancer published in another journal. The 12 Molecular Neurobiology retractions have trickled in over the past year or so, published before and after the Tumor Biology sweep.

A spokesperson at Springer confirmed that the 12 retracted papers in Molecular Neurobiology were related to the Tumor Biology retractions for fake peer review: Continue reading Springer purge of fake reviews takes down 10+ more neuroscience papers

Author of retracted gene editing paper alleges “bullying” by former PI

In the fall of 2015, out-of-work stem cell biologist Mavi Camarasa decided she had waited long enough. It had been three years since she and a colleague were, best they could tell, the first to successfully correct the most common cystic fibrosis mutation in stem cells derived from a patient.

But her former lab director, Daniel Bachiller, had blocked her from writing even a short report, she told Retraction Watch:

He said we are not submitting at this time, wait until [the project is] complete. “Wait, wait,” is the only answer I’d had from him ever.

Though she’d left the Spanish regenerative medicine lab in 2013 to take care of an ailing parent and had mostly been scooped by another group in April of that year, Camarasa thought she still might be able to get something out of the project. She hatched a plan to make him an offer he couldn’t refuse — an already accepted manuscript where all he would have to do is attach his name at the last minute.

But this story didn’t turn out exactly how she’d hoped — and illustrates how the pressure to publish can affect researchers at different levels in the lab.

Continue reading Author of retracted gene editing paper alleges “bullying” by former PI

NIH neuroscientist up to 16 retractions

Stanley Rapoport. Source: NIH

Neuroscientist Stanley Rapoport just can’t catch a break.

Rapoport, who’s based at National Institute on Aging, is continuing to experience fallout from his research collaborations, after multiple co-authors have been found to have committed misconduct.

Most recently, Rapoport has had four papers retracted in three journals, citing falsified data in a range of figures. Although the notices do not specify how the data falsification occurred, Jagadeesh Rao, who was recently found guilty of research misconduct, is corresponding author on all four papers.

Back in December, Rapoport told us that a “number of retractions [for] Rao are still in the works:” Continue reading NIH neuroscientist up to 16 retractions

Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12)

A diabetes journal has issued two notices of concern for papers co-authored by a researcher who took another publisher to court after it did the same thing — but ultimately lost.

The notices are for two papers co-authored by Mario Saad — who, after losing his legal battle with the American Diabetes Association, has since accumulated 12 retractions. Both notices — from the journal Diabetologia, published by Springer and the the European Association for the Study of Diabetes (EASD) — say they have alerted Saad to their concerns about some of the images in the papers, and the university where he is based was asked to investigate more than one year ago. Since the journal has not yet received any information from the University of Campinas in Brazil, however, it decided to issue expressions of concern for the two papers.

Here’s the text of the first notice:

Continue reading Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12)

Journal: Here’s why we didn’t retract this duplicated paper

Here’s something we don’t see every day: A journal explains in an erratum notice why it chose not to retract a paper that contains data published elsewhere.

According to the Journal of Business and Psychology, the authors violated the journal’s transparency policy by failing to disclose that they’d used the same data in their 2014 in three others. However, the editors ultimately concluded the current paper was different enough from the other three to save it from being retracted.

Here’s the erratum: Continue reading Journal: Here’s why we didn’t retract this duplicated paper

Top physicist loses another paper; tally now up to 7

A physics journal has retracted a paper from a leading physicist in India over duplication.

The paper’s first and corresponding Naba K. Sahoo has had six papers retracted for the same reason — four earlier this year and two last year.

The new retraction brings Sahoo’s total to seven, by our count.

The duplication allegations began several years ago, after Sahoo’s colleagues at Bhabha Atomic Research Centre (BARC), part of Indian government’s Department of Atomic Energy, accused him of plagiarizing his own work.

Thomas Lippert, editor-in chief of Applied Physics A: Material Science & Processing, told us: Continue reading Top physicist loses another paper; tally now up to 7

Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

Elizabeth Moylan
Rachel Burley

Over the decades, the concept of peer review has changed dramatically – so what does the future hold? That’s a question examined in a new report issued today by BioMed Central and Digital Science, based on discussions held during the SpotOn London conference. (Disclosure: Our co-founder Ivan Oransky spoke there.) We spoke with Elizabeth Moylan, Senior Editor Research Integrity at BioMed Central, and Rachel Burley, Publishing Director at BioMed Central about the central question posed by the report: What will peer review look like in the year 2030?

Retraction Watch: People have many complaints about peer review. What do you think are its most pressing flaws?

Continue reading Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Continue reading A shadow was cast on a bone researcher’s work. What are journals doing about his papers?